Significats de luminal breast en anglès

Background: Robust and precise molecular prognostic predictors for luminal breast cancer are required.

This study illustrates the value of extended follow-up in trials of luminal breast cancer.

Conclusions: We identified several key methylation sites and an mRNA signature for predicting luminal breast cancer prognosis.

Furthermore, PDEF is essential for luminal breast cancer cell survival and is required in models of endocrine resistance.

Methods: We compared methylation levels of normal and luminal breast cancer samples from The Cancer Genome Atlas dataset.

Antiestrogen or estrogen receptor (ER)-targeted therapies to block ER action remain the primary treatment of luminal breast cancers.

Here we describe patient-derived ER+ luminal breast tumor models for the study of intratumoral hormone and receptor action.

The transcription factor GATA3 is a key regulator of mammary gland development and a definitive marker of luminal breast cancer.

This study aimed to identify key methylation sites in luminal breast cancer, as well as precise molecular tools for predicting prognosis.

The signature exhibited effective and precise prediction of prognosis and may serve as a prognostic and diagnostic marker for luminal breast cancer.

Purpose: Luminal breast cancer has a long natural history, with recurrences continuing beyond 10 years after diagnosis.